Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
CTD_human |
|
|
|
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Kidney carcinoma associated with Xp11.2 translocation / TFE3 (ASPL-TFE3) gene fusion.
|
15992428 |
2005 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Renal cell carcinomas associated with Xp11.2 translocations ( TFE3 gene fusions) are rare tumors predominantly reported in children.
|
17580272 |
2007 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Renal cell carcinoma associated with TFE3 gene fusion in an elderly woman.
|
17905124 |
2007 |
Renal Cell Carcinoma
|
0.500 |
AlteredExpression
|
disease |
LHGDN |
Renal cell carcinoma associated with TFE3 gene fusion in an elderly woman.
|
17905124 |
2007 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Renal cell carcinomas (RCC) associated with Xp11.2 translocations (transcription factor E3 gene fusions) are rare tumors predominantly reported in children.
|
19815489 |
2009 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: radiological findings mimicking papillary subtype.
|
21182142 |
2011 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Renal cell carcinomas (RCCs) with Xp11 translocation (Xp11 RCC) constitute a distinctive molecular subtype characterized by chromosomal translocations involving the Xp11.2 locus, resulting in gene fusions between the TFE3 transcription factor with a second gene (usually ASPSCR1, PRCC, NONO, or SFPQ).
|
28411178 |
2017 |
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
TFE3-positive renal cell carcinoma occurring in three children with dysfunctional kidneys on immunosuppression.
|
28322484 |
2017 |
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
TFE3 regulates renal adenocarcinoma cell proliferation via activation of the mTOR pathway.
|
28713889 |
2017 |
Renal Cell Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
TFE3 fusions escape from controlling of mTOR signaling pathway and accumulate in the nucleus promoting genes expression in Xp11.2 translocation renal cell carcinomas.
|
30849994 |
2019 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Transcription factor E3 (TFE3) is a useful marker for tumors with Xp11.2 translocation, including alveolar soft part sarcoma and renal cell carcinoma.
|
31788112 |
2019 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A case of PSF-TFE3 gene fusion in Xp11.2 renal cell carcinoma with melanotic features.
|
25582502 |
2015 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A novel case of t(X;1)(p11.2;p34) in a renal cell carcinoma with TFE3 rearrangement and favorable outcome in a 57-year-old patient.
|
20620589 |
2010 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A recently described subtype of renal cell carcinoma (RCC) bearing chromosome translocations involving a breakpoint at Xp11 and resulting in gene fusions involving the TFE3 transcription factor gene often presents in the pediatric population.
|
17656236 |
2007 |
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
A retrospective review was conducted to describe the clinical characteristics and outcome of adult patients with metastatic Xp11.2 RCC who had strong TFE3 nuclear immunostaining and received anti-VEGF therapy.
|
20665500 |
2010 |
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
A total of five TFE3 gene fusions (PRCC-TFE3, ASPSCR1-TFE3, SFPQ-TFE3, NONO-TFE3, and CLTC-TFE3) and one TFEB gene fusion (MALAT1-TFEB) have been identified in RCC tumours and characterized at the mRNA transcript level.
|
25048860 |
2014 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Adult-onset renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: 3 case reports and review of literature.
|
29901594 |
2018 |
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
All 7 PRCC-TFE3 RCCs showed positive cathepsin K immunoreactivity.
|
28949976 |
2017 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Although rare, RBM10-TFE3 fusion variant (from chromosome X paracentric inversion), therefore, appears to be a recurrent molecular event in Xp11.2 RCCs.
|
26998913 |
2016 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Among a total of 1130 identified renal cell carcinomas, 21 cases (1.9%) showed rearrangement of the TFE3 (n = 20) or (TFEB) (n = 1) gene.
|
28106924 |
2017 |
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Among the 27 renal cell carcinomas with TFE3 strong positive immunostaining, 20 cases were diagnosed as Xp11 translocation renal cell carcinoma, and seven cases were diagnosed as clear cell renal cell carcinoma.
|
31175325 |
2019 |
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Any RCC positive for TFE3 and lacking a translocation should be tested for ALK expression and translocation.
|
27450657 |
2016 |
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Association with the cellular splicing machinery is therefore, a common feature of the proteins that become fused to TFE3 in papillary renal cell carcinomas.
|
11313942 |
2001 |